Trial Profile
Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus After Failure of a First-line Treatment With VEGF Inhibitor
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 07 Feb 2018
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms ORCHIDEE
- 28 Nov 2016 Status changed from recruiting to discontinued.
- 15 Dec 2015 Status changed from not yet recruiting to recruiting as per ClinicalTrials.gov record.
- 22 Jul 2015 Planned initiation date changed from 1 Feb 2015 to 1 Jul 2015 as reported by ClinicalTrials.gov.